Alex Koong

Alex Koong

Auto-generated profile, based on publicly available information

Alex Koong

Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TLTimothy A. Lin
Timothy A. Lin
ZMZachary McCaw
Zachary McCaw
AKAlex Koong
Alex Koong
CLChristine Lin
Christine Lin
JJJoseph Abi Jaoude
Joseph Abi Jaoude
ELEthan Ludmir
Ethan Ludmir
Purpose: Survival analyses of novel agents with long-term responders often exhibit differential hazard rates over time. Such proportional hazards violations (PHV) may reduce the power of the log-rank test and lead to misinterpretation of trial results. We aimed to characterize the incidence and study attributes associated with PHVs in phase III oncology trials and assess the utility of restricted mean survival time and maximum combination test as additional analyses. Experimental Design: Clinicaltrials.gov and PubMed were searched to identify two-arm, randomized, phase III superiority-design cancer trials with time-to-event primary endpoints and published results through 2020. Patient-level data were reconstructed from published Kaplan–Meier curves. PHVs were assessed using Schoenfeld residuals. Results: Three hundred fifty-seven Kaplan–Meier comparisons across 341 trials were analyzed, encompassing 292,831 enrolled patients. PHVs were identified in 85/357 [23.8%; 95% confidence interval (CI), 19.7%, 28.5%] comparisons. In multivariable analysis, non–overall survival endpoints [OR, 2.16 (95% CI, 1.21, 3.87); P = 0.009] were associated with higher odds of PHVs, and immunotherapy comparisons [OR 1.94 (95% CI, 0.98, 3.86); P = 0.058] were weakly suggestive of higher odds of PHVs. Few trials with PHVs (25/85, 29.4%) prespecified a statistical plan to account for PHVs. Fourteen trials with PHVs exhibited discordant statistical signals with restricted mean survival time or maximum combination test, of which 10 (71%) reported negative results. Conclusions: PHVs are common across therapy types, and attempts to account for PHVs in statistical design are lacking despite the potential for results exhibiting nonproportional hazards to be misinterpreted.

16 March 2023 in JMIR Formative Research
Verified
Journal Article
Open access
AKAlex Koong
Alex Koong
UGUlysses Grant Gardner
Ulysses Grant Gardner
JBJason Burton
Jason Burton
CSCaleb Stewart
Caleb Stewart
PTPetria Thompson
Petria Thompson
MRMichael Rooney
Michael Rooney
Background: Open access (OA) publishing represents an exciting opportunity to facilitate the dissemination of scientific information to global audiences. However, OA publishing is often associated with significant article processing charges (APCs) for authors, which may thus serve as a barrier to publication. Objective: In this observational cohort study, we aimed to characterize the landscape of OA publishing in oncology and, further, identify characteristics of oncology journals that are predictive of APCs. Methods: We identified oncology journals using the SCImago Journal & Country Rank database. All journals with an OA publication option and APC data openly available were included. We searched journal websites and tabulated journal characteristics, including APC amount (in US dollars), OA model (hybrid vs full), 2-year impact factor (IF), H-index, number of citable documents, modality/treatment specific (if applicable), and continent of origin. All APCs were converted to US-dollar equivalents for final analyses. Selecting variables with significant associations in the univariable analysis, we generated a multiple regression model to identify journal characteristics independently associated with OA APC amount. An audit of a random 10% sample of the data was independently performed by 2 authors to ensure data accuracy, precision, and reproducibility. Results: Of 367 oncology journals screened, 251 met the final inclusion criteria. The median APC was US $2957 (IQR 1958-3450). The majority of journals (n=156, 62%) adopted the hybrid OA publication model and were based in Europe (n=119, 47%) or North America (n=87, 35%). The median (IQR) APC for all journals was US $2957 (1958-3540). Twenty-five (10%) journals had APCs greater than US $4000. There were 10 (4%) journals that offered OA publication with no publication charge. Univariable testing showed that journals with a greater number of citable documents (P<.001), higher 2-year IF (P<.001), higher H-index (P<.001), and those using the hybrid OA model (P<.001), or originating in Europe or North America (P<.001) tended to have higher APCs. In our multivariable model, the number of citable documents (β=US $367, SD US $133; P=.006), 2-year IF (US $1144, SD US $177; P<.001), hybrid OA publishing model (US $991, SD US $189; P<.001), and North American origin (US $838, SD US $186; P<.001) persisted as significant predictors of processing charges. Conclusions: OA publication costs are greater in oncology journals that publish more citable articles, use the hybrid OA model, have a higher IF, and are based in North America or Europe. These findings may inform targeted action to help the oncology community fully appreciate the benefits of open science.

15 October 2024
Verified
Other
Open access
PDF file
TLTimothy A. Lin
Timothy A. Lin
ZMZachary McCaw
Zachary McCaw
AKAlex Koong
Alex Koong
CLChristine Lin
Christine Lin
JJJoseph Abi Jaoude
Joseph Abi Jaoude
ELEthan Ludmir
Ethan Ludmir
Data Supplement S1: Clinical context of trials from Table 3 with proportional hazards violations and discordant alternative survival assessments that were cited in NCCN guidelines or led to FDA drug approval.

15 October 2024
Verified
Other
Open access
PDF file
TLTimothy A. Lin
Timothy A. Lin
ZMZachary McCaw
Zachary McCaw
AKAlex Koong
Alex Koong
CLChristine Lin
Christine Lin
JJJoseph Abi Jaoude
Joseph Abi Jaoude
ELEthan Ludmir
Ethan Ludmir
Table S3: List of 341 trials included in the overall analysis. ADT, androgen deprivation therapy; mFOLFOX, folinic acid, fluorouracil, and oxaliplatin; FOLFIRI, folinic acid, fluorouracil, irinotecan; GM-CSF, granulocyte-macrophage colony-stimulating factor; R-DHAP; rituximab, dexamethasone, cytarabine, cisplatin; O-DHAP; ofatumumab, dexamethasone, cytarabine, cisplatin; EDP, etoposide doxorubicin cisplatin; G-CHOP, obintuzumab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisone; RCHOP, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, prednisone; VR-CAP, rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib; AC, Adriamycin with cyclophosphamide; T, paclitaxel; XT, capecitabine plus paclitaxel; GIST, gastrointestinal stromal tumor; IFN, interferon; 5FU, 5-fluorouracil; FA, folinic acid; recMAGE-A3, recombinant MAGE A-3; NGR-Htnf, NGR–human tumor necrosis factor; TACE, trans-arterial chemoembolization; T-DM1, Trastuzumab emtansine; Mf, mitomycin-C and fluoropyrimidine; iceMFP, intraperitoneal cisplatin (100 mg), intravenous mitomycin-C (15 mg/m(2)) on postoperative day 1, followed by oral doxifluridine for 12 months, and six monthly intravenous cisplatin (60 mg/m(2); RFA, radiofrequency ablation.

15 October 2024
Verified
Other
Open access
PDF file
TLTimothy A. Lin
Timothy A. Lin
ZMZachary McCaw
Zachary McCaw
AKAlex Koong
Alex Koong
CLChristine Lin
Christine Lin
JJJoseph Abi Jaoude
Joseph Abi Jaoude
ELEthan Ludmir
Ethan Ludmir
Figure S4 Scatter Plot of the negative natural logarithm of the p-values of the restricted mean survival time difference and the trial hazard ratio for all Kaplan-Meier comparisons in this study. Increasing values along the x-axis represent decreasing log-rank p-values, while increasing values along the y-axis represent decreasing RMST difference pvalues. Studies reporting a log-rank p-value or RMST difference p-value as an inequality (e.g., p-value <.001) were considered to have a p-value of 0.001 for the purposes of graphical representation on the graph and are represented by a cluster of points in the top right corner of the graph. The solid blue horizontal and vertical lines represent the x-value and y-values at which p = .05. The dashed black line represents a reference line with the equation y = x crossing through the origin. RMST-D, restricted mean survival time difference.

15 October 2024
Verified
Other
Open access
PDF file
TLTimothy A. Lin
Timothy A. Lin
ZMZachary McCaw
Zachary McCaw
AKAlex Koong
Alex Koong
CLChristine Lin
Christine Lin
JJJoseph Abi Jaoude
Joseph Abi Jaoude
ELEthan Ludmir
Ethan Ludmir
Table S1: Sensitivity analyses of univariable and multivariable logistic regressions using only overall survival (OS) comparisons for trials with co-primary endpoints (PEPs).